专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06849621B2 Piperidine compounds 失效
标题翻译：哌啶化合物
公开(公告)号：US06849621B2
公开(公告)日：2005-02-01
申请号：US10095134
申请日：2002-03-11
申请人： Stuart B. Rosenblum , Qingbei Zeng , Mwangi Wa Mutahi , Robert G. Aslanian , Pauline C. Ting , Neng-Yang Shih , Daniel M. Solomon , Jianhua Cao , Henry A. Vaccaro , Kevin D. McCormick , John J. Baldwin , Ge Li
发明人： Stuart B. Rosenblum , Qingbei Zeng , Mwangi Wa Mutahi , Robert G. Aslanian , Pauline C. Ting , Neng-Yang Shih , Daniel M. Solomon , Jianhua Cao , Henry A. Vaccaro , Kevin D. McCormick , John J. Baldwin , Ge Li
IPC分类号： C07D211/34 , A61K31/496 , A61P1/00 , A61P1/04 , A61P3/04 , A61P9/00 , A61P9/04 , A61P11/00 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/28 , A61P37/08 , A61P43/00 , C07D211/26 , C07D211/38 , C07D211/62 , C07D211/96 , C07D243/08 , C07D401/06 , C07D401/14 , C07D405/14 , C07D407/12 , C07D407/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/14 , C07D451/02 , C07D487/06 , A61K31/4545 , C07D403/06
CPC分类号： C07D401/14 , C07D211/26 , C07D211/38 , C07D211/62 , C07D211/96 , C07D243/08 , C07D401/06 , C07D407/12 , C07D407/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/14 , C07D451/02 , C07D487/06
摘要： Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I.Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I.Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H. receptor antagonist.
摘要翻译：所公开的新化合物还公开了包含式I化合物的药物组合物。还公开了治疗各种疾病或病症的方法，例如过敏，过敏诱发的气道反应和充血（例如，鼻充血）。还公开了使用式I化合物与下列化合物组合治疗各种疾病或病症的方法，例如过敏，过敏诱发的气道反应和充血（例如，鼻塞） H.受体拮抗剂。

2. 发明授权

US07238688B2 Piperidine compounds 失效
标题翻译：哌啶化合物
公开(公告)号：US07238688B2
公开(公告)日：2007-07-03
申请号：US10974329
申请日：2004-10-27
申请人： Stuart B. Rosenblum , Qingbei Zeng , Mwangi Wa Mutahi , Robert G. Aslanian , Pauline C. Ting , Neng-Yang Shih , Daniel M. Solomon , Jianhua Cao , Henry A. Vaccaro , Kevin D. McCormick , John J. Baldwin , Ge Li
发明人： Stuart B. Rosenblum , Qingbei Zeng , Mwangi Wa Mutahi , Robert G. Aslanian , Pauline C. Ting , Neng-Yang Shih , Daniel M. Solomon , Jianhua Cao , Henry A. Vaccaro , Kevin D. McCormick , John J. Baldwin , Ge Li
IPC分类号： A61K31/55 , C07D243/08 , C07D241/02 , C07D401/06 , C07D403/06
CPC分类号： C07D401/14 , C07D211/26 , C07D211/38 , C07D211/62 , C07D211/96 , C07D243/08 , C07D401/06 , C07D407/12 , C07D407/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/14 , C07D451/02 , C07D487/06
摘要： Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I.Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I.Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
摘要翻译：公开的是式的新化合物还公开了包含式I化合物的药物组合物。还公开了治疗各种疾病或病症的方法，例如过敏，过敏诱发的气道反应和充血（例如，鼻拥塞）。还公开了使用组合式I化合物来治疗各种疾病或病症的方法，例如过敏，过敏诱发的气道反应和充血（例如，鼻塞）具有H 1受体拮抗剂。

3. 发明授权

US07220735B2 Benzimidazolone histamine H3 antagonists 失效
标题翻译：苯并咪唑酮组胺H3拮抗剂
公开(公告)号：US07220735B2
公开(公告)日：2007-05-22
申请号：US10414943
申请日：2003-04-16
申请人： Pauline C. Ting , Robert G. Aslanian , Michael Y. Berlin , Christopher W. Boyce , Jianhua Cao , Pietro Mangiaracina , Kevin D. McCormick , Mwangi W. Mutahi , Stuart B. Rosenblum , Neng-Yang Shih , Daniel M. Solomon , Wing C. Tom , Qingbei Zeng
发明人： Pauline C. Ting , Robert G. Aslanian , Michael Y. Berlin , Christopher W. Boyce , Jianhua Cao , Pietro Mangiaracina , Kevin D. McCormick , Mwangi W. Mutahi , Stuart B. Rosenblum , Neng-Yang Shih , Daniel M. Solomon , Wing C. Tom , Qingbei Zeng
IPC分类号： A61K31/495
CPC分类号： C07D471/04 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14
摘要： Disclosed are novel compounds of the formula wherein R1 is benzimidazolone derivative, M1 and M2 are optionally substituted carbon or nitrogen, R2 includes optionally substituted aryl or heteroaryl, and the remaining variables are as defined in the specification, and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1 receptor antagonist.
摘要翻译：公开了下式的新化合物其中R 1是苯并咪唑酮衍生物，M 1和M 2是任选取代的碳或氮，R SUP > 2 包括任选取代的芳基或杂芳基，其余变量如说明书中所定义，其余变量如说明书中所定义; 还公开了包含式I化合物的药物组合物和使用式I化合物治疗各种疾病或病症如过敏，过敏引起的气道反应和充血（例如，鼻塞）的方法，以及使用式I化合物与H 1受体拮抗剂组合治疗所述疾病或病症。

4. 发明授权

US07105505B2 Benzimidazole derivatives useful as histamine H3 antagonists 失效
标题翻译：可用作组胺H3拮抗剂的苯并咪唑衍生物
公开(公告)号：US07105505B2
公开(公告)日：2006-09-12
申请号：US10417391
申请日：2003-04-16
申请人： Qingbei Zeng , Robert G. Aslanian , Michael Y. Berlin , Christopher W. Boyce , Jianhua Cao , Joseph A. Kozlowski , Pietro Mangiaracina , Kevin D. McCormick , Mwangi W. Mutahi , Stuart B. Rosenblum , Neng-Yang Shih , Daniel M. Solomon , Wing C. Tom
发明人： Qingbei Zeng , Robert G. Aslanian , Michael Y. Berlin , Christopher W. Boyce , Jianhua Cao , Joseph A. Kozlowski , Pietro Mangiaracina , Kevin D. McCormick , Mwangi W. Mutahi , Stuart B. Rosenblum , Neng-Yang Shih , Daniel M. Solomon , Wing C. Tom
IPC分类号： A61K31/495
CPC分类号： C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要： Disclosed are novel compounds of the formula wherein R1 is optionally substituted benzimidazolyl or a derivative thereof; R2 is optionally substituted aryl or heteroaryl; M1 and M2 are C(R3) or N; and the remaining variables are as defined in the specification; also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I, as well as methods of treating said diseases or conditions using the compounds of formula I in combination with an H1 receptor antagonist.
摘要翻译：公开了下式的新化合物，其中R 1是任选取代的苯并咪唑基或其衍生物; R 2是任选取代的芳基或杂芳基; M 1和M 2是C（R 3）或N; 剩余的变量如规范中所定义; 还公开了包含式I化合物的药物组合物和使用式I化合物治疗各种疾病或病症如过敏，过敏引起的气道反应和充血（例如，鼻塞）的方法，以及使用式I化合物与H 1受体拮抗剂组合治疗所述疾病或病症。

5. 发明授权

US07868005B2 Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity 有权
标题翻译：吡嗪基取代的哌嗪 - 哌啶与CXCR3拮抗剂活性
公开(公告)号：US07868005B2
公开(公告)日：2011-01-11
申请号：US11354138
申请日：2006-02-14
申请人： Stuart B. Rosenblum , Seong Heon Kim , Qingbei Zeng , Michael K. C. Wong , Gopinadhan N. Anilkumar , Yueheng Jiang , Wensheng Yu , Joseph A. Kozlowski , Neng-Yang Shih , Bandarpalle B. Shankar , Brian F. McGuinness , Guizhen Dong , Lisa Guise Zawacki , Douglas W. Hobbs , John J. Baldwin , Yuefei Shao
发明人： Stuart B. Rosenblum , Seong Heon Kim , Qingbei Zeng , Michael K. C. Wong , Gopinadhan N. Anilkumar , Yueheng Jiang , Wensheng Yu , Joseph A. Kozlowski , Neng-Yang Shih , Bandarpalle B. Shankar , Brian F. McGuinness , Guizhen Dong , Lisa Guise Zawacki , Douglas W. Hobbs , John J. Baldwin , Yuefei Shao
IPC分类号： C07D241/04 , C07D401/14 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4436 , A61K31/695 , C07F7/18 , A61P25/28 , A61P35/00 , A61P29/00
CPC分类号： C07D405/14 , C07D401/12 , C07D401/14 , C07D413/14 , C07D417/14
摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
摘要翻译：本申请公开了所述化合物或所述前体药物的所述化合物或其药学上可接受的盐，溶剂合物或酯的化合物或对映异构体，立体异构体，旋转异构体，互变异构体或前药，所述化合物具有式1所示的一般结构：及其药学上可接受的盐，溶剂化物和酯。还公开了治疗趋化因子介导的疾病的方法，例如姑息治疗，疗效治疗，某些疾病和疾病如炎性疾病的预防性治疗（非限制性实例，牛皮癣），自身免疫性疾病（非限制性的例如，类风湿性关节炎，多发性硬化症），移植排斥反应（非限制性实例包括，同种异体移植排斥反应，异种移植物排斥），感染性疾病（例如结核性麻风病），固定药物爆发，皮肤迟发型超敏反应应答，眼部炎症，I型糖尿病，病毒性脑膜炎和使用式1的化合物的肿瘤。

6. 发明申请

US20050113383A1 Novel non-imidazole compounds 失效
标题翻译：新型非咪唑化合物
公开(公告)号：US20050113383A1
公开(公告)日：2005-05-26
申请号：US10974329
申请日：2004-10-27
申请人： Stuart Rosenblum , Qingbei Zeng , Mwangi Mutahi , Robert Aslanian , Pauline Ting , Neng-Yang Shih , Daniel Solomon , Jianhua Cao , Henry Vaccaro , Kevin McCormick , John Baldwin , Ge Li
发明人： Stuart Rosenblum , Qingbei Zeng , Mwangi Mutahi , Robert Aslanian , Pauline Ting , Neng-Yang Shih , Daniel Solomon , Jianhua Cao , Henry Vaccaro , Kevin McCormick , John Baldwin , Ge Li
IPC分类号： C07D211/34 , A61K31/496 , A61P1/00 , A61P1/04 , A61P3/04 , A61P9/00 , A61P9/04 , A61P11/00 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/20 , A61P25/28 , A61P37/08 , A61P43/00 , C07D211/26 , C07D211/38 , C07D211/62 , C07D211/96 , C07D243/08 , C07D401/06 , C07D401/14 , C07D405/14 , C07D407/12 , C07D407/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/14 , C07D451/02 , C07D487/06 , A61K31/4545 , C07D43/14 , C07D45/14
CPC分类号： C07D401/14 , C07D211/26 , C07D211/38 , C07D211/62 , C07D211/96 , C07D243/08 , C07D401/06 , C07D407/12 , C07D407/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/14 , C07D451/02 , C07D487/06
摘要： Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.
摘要翻译：公开的是式的新化合物还公开了包含式I化合物的药物组合物。还公开了治疗各种疾病或病症的方法，例如过敏，过敏诱发的气道反应和充血（例如，鼻拥塞）。还公开了使用组合式I化合物来治疗各种疾病或病症的方法，例如过敏，过敏诱发的气道反应和充血（例如，鼻塞）具有H 1受体拮抗剂。

7. 发明申请

US20120157466A1 HETEROCYCLIC COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY 审中-公开
标题翻译：具有CXCR3拮抗剂活性的杂环化合物
公开(公告)号：US20120157466A1
公开(公告)日：2012-06-21
申请号：US12519970
申请日：2007-12-20
申请人： Qingbei Zeng , Stuart B. Rosenblum , Joseph A. Kozlowski , Neng-Yang Shih , Brian F. McGuinness , Douglas W. Hobbs
发明人： Qingbei Zeng , Stuart B. Rosenblum , Joseph A. Kozlowski , Neng-Yang Shih , Brian F. McGuinness , Douglas W. Hobbs
IPC分类号： A61K31/519 , C07D401/14 , C07D473/32 , A61K31/52 , A61K31/496 , A61P29/00 , A61P37/00 , C07D471/04 , A61K31/506
CPC分类号： C07D401/14
摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 or Formula 5: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
摘要翻译：本申请公开了所述化合物或所述前体药物的所述化合物或其药学上可接受的盐，溶剂合物或酯的化合物或对映异构体，立体异构体，旋转异构体，互变异构体或前药，所述化合物具有式1所示的一般结构或式5：或其药学上可接受的盐，溶剂合物或酯。还公开了治疗趋化因子介导的疾病的方法，例如姑息治疗，治疗疗法，某些疾病和疾病如炎性疾病的预防性治疗（非限制性实例，包括牛皮癣），自身免疫疾病（非限制性实例（传染性疾病（例如结核性麻风病），固定药物爆发，皮肤迟发型超敏反应，眼部炎症反应（例如，类风湿性关节炎，多发性硬化症），移植物排斥反应（非限制性实例包括同种异体移植物排斥反应，，I型糖尿病，病毒性脑膜炎和使用式1的化合物的肿瘤。

8. 发明授权

US08143305B2 2,3-substituted indole derivatives for treating viral infections 失效
标题翻译：用于治疗病毒感染的2,3-取代的吲哚衍生物
公开(公告)号：US08143305B2
公开(公告)日：2012-03-27
申请号：US12675897
申请日：2008-08-27
申请人： Gopinadhan N. Anilkumar , Frank Bennett , Tin-Yau Chan , Kevin X. Chen , Mousumi Sannigrahi , Francisco Velazquez , Srikanth Venkatraman , Qingbei Zeng , Jose S. Duca , Charles A. Lesburg , Joseph A. Kozlowski , F. George Njoroge , Stuart B. Rosenblum , Neng-Yang Shih , Stephen J. Gavalas , Yueheng Jiang , Patrick A. Pinto , Haiyan Pu , Oleg B. Selyutin , Bancha Vibulbhan , Li Wang , Wanli Wu , Weiying Yang , Yuhua Huang , Hsueh-Cheng Huang , Robert Palermo , Boris Feld
发明人： Gopinadhan N. Anilkumar , Frank Bennett , Tin-Yau Chan , Kevin X. Chen , Mousumi Sannigrahi , Francisco Velazquez , Srikanth Venkatraman , Qingbei Zeng , Jose S. Duca , Charles A. Lesburg , Joseph A. Kozlowski , F. George Njoroge , Stuart B. Rosenblum , Neng-Yang Shih , Stephen J. Gavalas , Yueheng Jiang , Patrick A. Pinto , Haiyan Pu , Oleg B. Selyutin , Bancha Vibulbhan , Li Wang , Wanli Wu , Weiying Yang , Yuhua Huang , Hsueh-Cheng Huang , Robert Palermo , Boris Feld
IPC分类号： A01N43/38 , A61K31/40 , C07D209/04
CPC分类号： C07D417/14 , C07D209/42 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14
摘要： The present invention relates to 2,3-Substituted Indole Derivatives, compositions comprising at least one 2,3-Substituted Indole Derivative, and methods of using the 2,3-Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.
摘要翻译：本发明涉及2,3-取代的吲哚衍生物，包含至少一种2,3-取代的吲哚衍生物的组合物和使用2,3-取代的吲哚衍生物用于治疗或预防病毒感染或病毒相关的方法病人无序。

9. 发明授权

US07879838B2 Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity 有权
标题翻译：具有CXCR3拮抗活性的杂芳基取代的吡嗪基 - 哌嗪 - 哌啶
公开(公告)号：US07879838B2
公开(公告)日：2011-02-01
申请号：US11353474
申请日：2006-02-14
申请人： Qingbei Zeng , De-Yi Yang , Stuart B. Rosenblum , Michael K. C. Wong , Gopinadhan N. Anilkumar , Seong Heon Kim , Wensheng Yu , Joseph A. Kozlowski , Neng-Yang Shih , Brian F. McGuinness , Lisa Guise Zawacki , Doublas W. Hobbs
发明人： Qingbei Zeng , De-Yi Yang , Stuart B. Rosenblum , Michael K. C. Wong , Gopinadhan N. Anilkumar , Seong Heon Kim , Wensheng Yu , Joseph A. Kozlowski , Neng-Yang Shih , Brian F. McGuinness , Lisa Guise Zawacki , Doublas W. Hobbs
IPC分类号： A01N43/00 , A61K31/00 , A61K31/535 , A61K31/497 , C07D413/00 , C07D403/00 , C07D241/02
CPC分类号： C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D487/04
摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.
摘要翻译：本申请公开了所述化合物或所述前药的所述化合物或其对映异构体，立体异构体，旋转异构体，互变异构体，外消旋体或前药，或所述前药的所述化合物，所述化合物具有式1所示的一般结构：和其药学上可接受的盐，溶剂合物或酯。还公开了治疗趋化因子介导的疾病的方法，例如姑息治疗，疗效治疗，某些疾病和疾病如炎性疾病的预防性治疗（非限制性实例，牛皮癣），自身免疫性疾病（非限制性的例如，类风湿性关节炎，多发性硬化症），移植排斥反应（非限制性实例包括，同种异体移植排斥反应，异种移植物排斥），感染性疾病（例如结核性麻风病），固定药物爆发，皮肤迟发型超敏反应应答，眼部炎症，I型糖尿病，病毒性脑膜炎和使用式1的化合物的肿瘤。

10. 发明授权

US08614229B2 Substituted indole derivatives and methods of use thereof 有权
标题翻译：取代的吲哚衍生物及其使用方法
公开(公告)号：US08614229B2
公开(公告)日：2013-12-24
申请号：US12675891
申请日：2008-08-27
申请人： Gopinadhan N. Anilkumar , Frank Bennett , Tin-Yau Chan , Kevin X. Chen , Mousumi Sannigrahi , Francisco Velazquez , Srikanth Venkatraman , Qingbei Zeng , Jose S. Duca , Charles A. Lesburg , Joseph A. Kozlowski , F. George Njoroge , Stuart B. Rosenblum , Neng-Yang Shih
发明人： Gopinadhan N. Anilkumar , Frank Bennett , Tin-Yau Chan , Kevin X. Chen , Mousumi Sannigrahi , Francisco Velazquez , Srikanth Venkatraman , Qingbei Zeng , Jose S. Duca , Charles A. Lesburg , Joseph A. Kozlowski , F. George Njoroge , Stuart B. Rosenblum , Neng-Yang Shih
IPC分类号： A61K31/47 , A61K31/4402 , A61K31/426 , A61K31/428 , A61K31/4184 , A61K31/404 , C07D239/96 , C07D239/88 , C07D241/44 , C07D471/04 , C07D215/18 , C07D401/04 , C07D211/88 , C07D277/18 , C07D487/04 , C07D275/04 , C07D249/18
CPC分类号： C07D403/04 , C07D401/04
摘要： The present invention relates to Substituted Indole Derivatives, compositions comprising at least one Substituted Indole Derivative, and methods of using these Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient.
摘要翻译：本发明涉及取代的吲哚衍生物，包含至少一种取代的吲哚衍生物的组合物，以及使用这些取代的吲哚衍生物来治疗或预防患者的病毒感染或病毒相关病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式